BioCentury
ARTICLE | Company News

Celgene, Accord settle Revlimid patent litigation

July 13, 2018 6:54 PM UTC

Celgene Corp. (NASDAQ:CELG) granted Accord Healthcare Ltd. (Middlesex, U.K.) rights to market an authorized generic version of cancer and hematology drug Revlimid lenalidomide starting on Jan. 18, 2022, in the U.K., according to a SEC filing. Accord will be able to market the generic in "various other European countries," starting on Feb. 18, 2022. The deal settles patent litigation between the companies.

Last June, Accord filed lawsuits in the U.K. against Celgene seeking to revoke three of Celgene's U.K. patents protecting Revlimid, including a supplementary protection certificate associated with a composition of matter patent that expires in June 2022. Accord amended its challenge to include a fourth, recently granted U.K. patent...

BCIQ Company Profiles

Celgene Corp.